275 related articles for article (PubMed ID: 15386423)
1. A recombinant humanized anti-insulin-like growth factor receptor type I antibody (h7C10) enhances the antitumor activity of vinorelbine and anti-epidermal growth factor receptor therapy against human cancer xenografts.
Goetsch L; Gonzalez A; Leger O; Beck A; Pauwels PJ; Haeuw JF; Corvaia N
Int J Cancer; 2005 Jan; 113(2):316-28. PubMed ID: 15386423
[TBL] [Abstract][Full Text] [Related]
2. Growth-inhibitory effects of human anti-insulin-like growth factor-I receptor antibody (A12) in an orthotopic nude mouse model of anaplastic thyroid carcinoma.
Wang Z; Chakravarty G; Kim S; Yazici YD; Younes MN; Jasser SA; Santillan AA; Bucana CD; El-Naggar AK; Myers JN
Clin Cancer Res; 2006 Aug; 12(15):4755-65. PubMed ID: 16899627
[TBL] [Abstract][Full Text] [Related]
3. Insulin-like growth factor receptor as a therapeutic target in head and neck cancer.
Barnes CJ; Ohshiro K; Rayala SK; El-Naggar AK; Kumar R
Clin Cancer Res; 2007 Jul; 13(14):4291-9. PubMed ID: 17634559
[TBL] [Abstract][Full Text] [Related]
4. Recombinant human insulin-like growth factor binding protein 3 inhibits growth of human epidermal growth factor receptor-2-overexpressing breast tumors and potentiates herceptin activity in vivo.
Jerome L; Alami N; Belanger S; Page V; Yu Q; Paterson J; Shiry L; Pegram M; Leyland-Jones B
Cancer Res; 2006 Jul; 66(14):7245-52. PubMed ID: 16849573
[TBL] [Abstract][Full Text] [Related]
5. A chimeric humanized single-chain antibody against the type I insulin-like growth factor (IGF) receptor renders breast cancer cells refractory to the mitogenic effects of IGF-I.
Sachdev D; Li SL; Hartell JS; Fujita-Yamaguchi Y; Miller JS; Yee D
Cancer Res; 2003 Feb; 63(3):627-35. PubMed ID: 12566306
[TBL] [Abstract][Full Text] [Related]
6. A fully human monoclonal antibody to the insulin-like growth factor I receptor blocks ligand-dependent signaling and inhibits human tumor growth in vivo.
Burtrum D; Zhu Z; Lu D; Anderson DM; Prewett M; Pereira DS; Bassi R; Abdullah R; Hooper AT; Koo H; Jimenez X; Johnson D; Apblett R; Kussie P; Bohlen P; Witte L; Hicklin DJ; Ludwig DL
Cancer Res; 2003 Dec; 63(24):8912-21. PubMed ID: 14695208
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of hepatocellular carcinoma cell growth by an anti-insulin-like growth factor-I receptor monoclonal antibody.
Yue L; Wang Y; Wang H; Gao H; Liang J; Sui A; Xiang J; Zhou F; Xu C; Zhao W; Liang W; Yao R
Oncol Rep; 2012 Oct; 28(4):1453-60. PubMed ID: 22895605
[TBL] [Abstract][Full Text] [Related]
8. Combination therapy enhances the inhibition of tumor growth with the fully human anti-type 1 insulin-like growth factor receptor monoclonal antibody CP-751,871.
Cohen BD; Baker DA; Soderstrom C; Tkalcevic G; Rossi AM; Miller PE; Tengowski MW; Wang F; Gualberto A; Beebe JS; Moyer JD
Clin Cancer Res; 2005 Mar; 11(5):2063-73. PubMed ID: 15756033
[TBL] [Abstract][Full Text] [Related]
9. Combined effects of tamoxifen and a chimeric humanized single chain antibody against the type I IGF receptor on breast tumor growth in vivo.
Ye JJ; Liang SJ; Guo N; Li SL; Wu AM; Giannini S; Sachdev D; Yee D; Brünner N; Ikle D; Fujita-Yamaguchi Y
Horm Metab Res; 2003; 35(11-12):836-42. PubMed ID: 14710366
[TBL] [Abstract][Full Text] [Related]
10. Molecular mechanisms involved in activity of h7C10, a humanized monoclonal antibody, to IGF-1 receptor.
Broussas M; Dupont J; Gonzalez A; Blaecke A; Fournier M; Corvaïa N; Goetsch L
Int J Cancer; 2009 May; 124(10):2281-93. PubMed ID: 19165858
[TBL] [Abstract][Full Text] [Related]
11. Functional responses and in vivo anti-tumour activity of h7C10: a humanised monoclonal antibody with neutralising activity against the insulin-like growth factor-1 (IGF-1) receptor and insulin/IGF-1 hybrid receptors.
Pandini G; Wurch T; Akla B; Corvaia N; Belfiore A; Goetsch L
Eur J Cancer; 2007 May; 43(8):1318-27. PubMed ID: 17451939
[TBL] [Abstract][Full Text] [Related]
12. [shRNA-mediated insulin-like growth factor I receptor gene silencing inhibits cell proliferation, induces cell apoptosis, and suppresses tumor growth in non-small cell lung cancer: in vitro and in vivo experiments].
Dong AQ; Kong MJ; Ma ZY; Qian JF; Fan JQ; Xu XH
Zhonghua Yi Xue Za Zhi; 2007 Jun; 87(21):1506-9. PubMed ID: 17785094
[TBL] [Abstract][Full Text] [Related]
13. An anti-insulin-like growth factor I receptor antibody that is a potent inhibitor of cancer cell proliferation.
Maloney EK; McLaughlin JL; Dagdigian NE; Garrett LM; Connors KM; Zhou XM; Blättler WA; Chittenden T; Singh R
Cancer Res; 2003 Aug; 63(16):5073-83. PubMed ID: 12941837
[TBL] [Abstract][Full Text] [Related]
14. Superior antitumor activity of a novel bispecific antibody cotargeting human epidermal growth factor receptor 2 and type I insulin-like growth factor receptor.
Chen C; Zhang Y; Zhang Y; Li J; Tsao SW; Zhang MY
Mol Cancer Ther; 2014 Jan; 13(1):90-100. PubMed ID: 24227890
[TBL] [Abstract][Full Text] [Related]
15. Down-regulation of insulin receptor by antibodies against the type I insulin-like growth factor receptor: implications for anti-insulin-like growth factor therapy in breast cancer.
Sachdev D; Singh R; Fujita-Yamaguchi Y; Yee D
Cancer Res; 2006 Feb; 66(4):2391-402. PubMed ID: 16489046
[TBL] [Abstract][Full Text] [Related]
16. Insulin-like growth factor-I receptor signaling in tamoxifen-resistant breast cancer: a supporting role to the epidermal growth factor receptor.
Knowlden JM; Hutcheson IR; Barrow D; Gee JM; Nicholson RI
Endocrinology; 2005 Nov; 146(11):4609-18. PubMed ID: 16037379
[TBL] [Abstract][Full Text] [Related]
17. Feedback mechanisms promote cooperativity for small molecule inhibitors of epidermal and insulin-like growth factor receptors.
Buck E; Eyzaguirre A; Rosenfeld-Franklin M; Thomson S; Mulvihill M; Barr S; Brown E; O'Connor M; Yao Y; Pachter J; Miglarese M; Epstein D; Iwata KK; Haley JD; Gibson NW; Ji QS
Cancer Res; 2008 Oct; 68(20):8322-32. PubMed ID: 18922904
[TBL] [Abstract][Full Text] [Related]
18. Insulin-like growth factor-1 receptor inhibition induces a resistance mechanism via the epidermal growth factor receptor/HER3/AKT signaling pathway: rational basis for cotargeting insulin-like growth factor-1 receptor and epidermal growth factor receptor in hepatocellular carcinoma.
Desbois-Mouthon C; Baron A; Blivet-Van Eggelpoël MJ; Fartoux L; Venot C; Bladt F; Housset C; Rosmorduc O
Clin Cancer Res; 2009 Sep; 15(17):5445-56. PubMed ID: 19706799
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase.
Sirotnak FM; Zakowski MF; Miller VA; Scher HI; Kris MG
Clin Cancer Res; 2000 Dec; 6(12):4885-92. PubMed ID: 11156248
[TBL] [Abstract][Full Text] [Related]
20. Combination of two insulin-like growth factor-I receptor inhibitory antibodies targeting distinct epitopes leads to an enhanced antitumor response.
Dong J; Demarest SJ; Sereno A; Tamraz S; Langley E; Doern A; Snipas T; Perron K; Joseph I; Glaser SM; Ho SN; Reff ME; Hariharan K
Mol Cancer Ther; 2010 Sep; 9(9):2593-604. PubMed ID: 20716637
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
